Location Haddonfield, New Jersey, United States Regions Greater Philadelphia Area, East Coast, Northeastern US Gender Male
Dr Andrew is the founder and Chief Scientific Officer of Andrew Technologies, LLC. He is the co-inventor of Tissue Liquefaction Technology® (TLT). Andrew Technologies’ HydraSolve® is the second clinical application of TLT, the first being the AquaLase® Liquefaction Device, a small-incision cataract removal technology on Alcon’s premier cataract
machine, the INFINITI® Vision System, used routinely in more than 50 countries.
Dr Andrew is a board-certified ophthalmologist with more than 25 years’ experience. He received his medical degree from Jefferson Medical College in Philadelphia, PA, and served his residency at Hahnemann University Hospital in Philadelphia. His scientific background includes basic science research in endocrinology, immunology, and biochemistry. Dr Andrew holds 8 issued US patents with 6 pending, as well as 23 issued foreign patents.
